The combination of PARPi (Talazoparib – TAL) and DNMTi (Decitabine – DAC) functions synergistically to inhibit PCa cell lines and patient-derived PTOs.
Circulating tumor DNA (ctDNA) purity can be used to predict therapy response of metastatic castration-resistant prostate cancer (mCRPC) to PD-L1/PARP1 inhibition.
We present a computational toolkit to analyse 5mC and 5hmC modifications at scale and describe its performance on a novel liquid biopsy dataset.
Alfonso Bellacosa, MD, PhD, a Professor in the Nuclear Dynamics and Cancer Research Program and Johnathan R. Whetstine, PhD, the Jack Schultz Chair in Basic Science, both at Fox Chase.
Professor Ellen Heitzer’s lab at the Medical University of Graz analysed eight samples from localised PCa, metastatic PCa, and suspicious Pca (men with elevated serum PSA and/or suspect digital rectal examination but negative biopsy) using the duet multiomics solution evoC.
As well as helping researchers identify tumour DNA amid the soup of regular cell-free DNA, the fact that different tissues have distinct methylation patterns can help explain where the cell-free DNA might be coming from. “There are many advantages to being able to study epigenomics in concert with genomic features,” says Dawson.
Learn how 6-base sequencing reveals 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) have important roles in the regulation of genome dynamics. Deregulation of TET can spur an increase of 5hmC in heterochromatin which could potentially be an early biomarker of genome dysfunction that lead to diseases.
Download this poster Credits Fabio Puddu¹ Annelie Johansson¹ Aurélie Modat¹ Jamie Scotcher¹ Riccha Sethi¹ Nick Harding¹ Mark Hill¹ Ermira Lleshi¹ Casper Lumby¹ Jean Teyssandier¹ Michael
To address the difficulties of analysing methylation data, this poster presents modality, an efficient and scalable analysis package for 5- and 6-base genomes.
This poster demonstrates that the combination of 5mC and 5hmC is highly effective for early-stage CRC detection in cfDNA – read it now.